BDSX stock icon

Biodesix
BDSX

$1.69
1.81%
 

About: Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Employees: 217

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 3 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

56% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 9

43% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 7

8% more funds holding

Funds holding: 38 [Q4 2023] → 41 (+3) [Q1 2024]

2.18% less ownership

Funds ownership: 18.69% [Q4 2023] → 16.51% (-2.18%) [Q1 2024]

32% less capital invested

Capital invested by funds: $33.8M [Q4 2023] → $22.9M (-$10.9M) [Q1 2024]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q4 2023] → 1 (-1) [Q1 2024]

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $4K

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$2.80
66%
upside
Avg. target
$3.10
83%
upside
High target
$3.50
107%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
TD Cowen
Dan Brennan
66%upside
$2.8
Buy
Initiated
13 May 2024
Lake Street
78%upside
$3
Buy
Initiated
3 May 2024
Canaccord Genuity
Kyle Mikson
107%upside
$3.5
Buy
Reiterated
4 Mar 2024

Financial journalist opinion